Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00857532
Other study ID # 18F-AV-45-A12
Secondary ID 5R43NS063607-02
Status Completed
Phase Phase 2
First received March 5, 2009
Last updated February 1, 2013
Start date January 2009
Est. completion date November 2011

Study information

Verified date February 2013
Source Avid Radiopharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date November 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender Both
Age group 60 Years and older
Eligibility Inclusion Criteria:

- Subjects may be enrolled if they (inclusion criteria):

- Are males or females =60 years of age

- Meet research diagnostic criteria for Parkinson's disease:

- Diagnosis of a parkinsonian syndrome

- Bradykinesia (slowness of initiation of voluntary movement with progressive reduction in speed and amplitude of repetitive actions)

- At least one of the following: muscle rigidity, rest tremor, postural instability not due to visual, vestibular, cerebellar or proprioceptive causes

- Supportive criteria for diagnosis of PD (two or more required)

- Unilateral onset of symptoms and persistent asymmetry

- Rest tremor present

- Progressive illness

- Excellent response to levodopa with dyskinesias

- Levodopa response for 5 years or more

- Clinical course of 10 years or more

- Have the ability to lie flat and tolerate a 10 minute PET scan.

Exclusion Criteria:

- Subjects may not be enrolled if any of the following are present (exclusion criteria):

- History of repeated strokes, repeated head injury, definite encephalitis

- Use of neuroleptics at onset of symptoms

- Sustained remission

- Strictly unilateral feature persisting > three years after onset

- Significant supranuclear gaze palsy

- Cerebellar, pyramidal and early severe autonomic findings

- Early severe dementia suggesting a diagnosis of dementia with Lewy bodies (DLB)

- Imaging study showing structural abnormality that could explain parkinsonism

- Negative response to an adequate levodopa trial

- Current clinically significant psychiatric disease that prohibits providing informed consent or participation in the study

- Current clinically significant endocrine or metabolic disease, pulmonary,

- Women of childbearing potential who are not two or more years post menopausal or surgically sterilized

- Have received any investigational medications, or have participated in a trial with investigational medications within the last 30 days

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Drug:
florbetapir F 18
10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection

Locations

Country Name City State
United States Research Site Philadelphia Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Avid Radiopharmaceuticals National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Cortical Amyloid Burden Standardized uptake value ratios (SUVR) were calculated and compared between subjects with PD and controls. Subjects with Parkinson's Disease (PD) were stratified into one of three groups based on performance on the age and education adjusted Mattis Dementia Rating Scale (DRS-2). The age and education adjusted DRS-2 ranges from 0 (lowest cognitive function) to 20 (highest cognitive function). SUVR is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum. SUVR values higher than 1 indicate greater amyloid burden in the predefined cortical regions as compared to cerebellum whereas scores less than 1 indicate the opposite. This outcome measure only reports data from the subjects analyzed in this study, the data from normal controls was obtained from a pre-existing database and is not reported here. 50-60 min after injection No
Secondary Correlation Between Global Amyloid Burden and Clinical Measures of Cognitive Decline. Correlation between amyloid burden (global florbetapir SUVR) and cognitive decline (DRS-2 score) was determined using Spearman's rank order correlation method where SUVR was the dependent variable and the DRS-2 score was the independent variable. This analysis was performed for total DRS-2 score and the five DRS-2 subscale scores. The subscales (score range) are: Attention (0-37), Initiation/Perseveration (0-37), Construction (0-6), Conceptualization (0-39) and Memory (0-25). The total DRS-2 score is the sum of the subscale scores and ranges from 0-144. Higher DRS-2 scores indicate greater cognitive function. 50-60 min after injection No
Secondary Correlation of Florbetapir SUVR With CSF Biomarker Values Correlation between amyloid burden (florbetapir SUVR) and cerebrospinal fluid (CSF) biomarker values (amyloid beta, tau and phospho-tau) was determined using Spearman's rank order correlation in a subset of subjects undergoing CSF analysis where SUVR was the dependent variable and CSF biomarker values were the independent variables. 50-60 min after injection No
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A
Completed NCT02927691 - Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial Phase 2